{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:49:56Z","timestamp":1791272996827,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.msard.2022.104246","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T03:30:56Z","timestamp":1665977456000},"page":"104246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Intravenous ofatumumab treatment of multiple sclerosis and related disorders: An observational study"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2737-8305","authenticated-orcid":false,"given":"Sahla","family":"El Mahdaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe","family":"Romme Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malthe Faurschou","family":"Wandall-Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2022.104246_bib0001","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2022.104246_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw. Open"},{"issue":"11","key":"10.1016\/j.msard.2022.104246_bib0003","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/rheumatology\/ket257","article-title":"Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: Results from a single centre","volume":"52","author":"Besada","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.msard.2022.104246_bib0004","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2018.02.010","article-title":"Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study","volume":"48","author":"Boleto","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.msard.2022.104246_bib0005","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/brain\/awy301","article-title":"Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis","volume":"142","author":"Von Essen","year":"2019","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.msard.2022.104246_bib0006","article-title":"A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis","volume":"6","author":"Evertsson","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"4","key":"10.1016\/j.msard.2022.104246_bib0007","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2022.104246_bib0008","unstructured":"Gerds, T.A. (2019) prodlim: product-limit estimation for censored event history analysis."},{"issue":"1","key":"10.1016\/j.msard.2022.104246_bib0009","doi-asserted-by":"crossref","first-page":"e918","DOI":"10.1212\/NXI.0000000000000918","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD: Part 1","volume":"8","author":"Graf","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2022.104246_bib0010","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1212\/NXI.0000000000000919","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2","volume":"8","author":"Graf","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.msard.2022.104246_bib0011","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2022.104246_bib0012","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Supplement to: ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2022.104246_bib0013","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.msard.2022.104246_bib0014","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2022.104246_bib0015","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.104246_bib0016","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"9805","key":"10.1016\/j.msard.2022.104246_bib0017","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.msard.2022.104246_bib0018","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.msard.2022.104246_bib0019","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","article-title":"Complement activation plays a key role in the side-effects of rituximab treatment","volume":"115","author":"Van Der Kolk","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.msard.2022.104246_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102466","article-title":"Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia","volume":"19","author":"Kridin","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2022.104246_bib0021","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jneuroim.2019.04.017","article-title":"B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients","volume":"332","author":"Lovett-Racke","year":"2019","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.msard.2022.104246_bib0022","doi-asserted-by":"crossref","first-page":"e01921","DOI":"10.1002\/brb3.1921","article-title":"The danish multiple sclerosis registry","volume":"11","author":"Magyari","year":"2021","journal-title":"Brain Behav"},{"issue":"3","key":"10.1016\/j.msard.2022.104246_bib0023","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Supplement to: ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.104246_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102988","article-title":"Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases","volume":"52","author":"Oksbjerg","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104246_bib0025","unstructured":"Pinheiro, J., Bates, D., DebRoy, S., Sarkar, D., et\u00a0al. (2021) nlme: linear and nonlinear mixed effects models description."},{"key":"10.1016\/j.msard.2022.104246_bib0026","series-title":"R: A language and environment for statistical computing","year":"2021"},{"issue":"2","key":"10.1016\/j.msard.2022.104246_bib0027","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1586\/era.10.223","article-title":"Ofatumumab for newly diagnosed and relapsed\/refractory chronic lymphocytic leukemia","volume":"11","author":"Reagan","year":"2011","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"2","key":"10.1016\/j.msard.2022.104246_bib0028","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple Sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.msard.2022.104246_bib0029","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2022.104246_bib0030","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40263-020-00704-w","article-title":"Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis","volume":"34","author":"Sellebjerg","year":"2020","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.msard.2022.104246_bib0031","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0000000000000125","article-title":"Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study","volume":"82","author":"Sorensen","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2022.104246_bib0032","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2022.104246_bib0033","unstructured":"U.S. Department of Health and Human Services (2017) Common terminology criteria for adverse events (CTCAE) version 5.0."},{"issue":"9","key":"10.1016\/j.msard.2022.104246_bib0034","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822007507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822007507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:07:21Z","timestamp":1761901641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822007507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":34,"alternative-id":["S2211034822007507"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104246","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous ofatumumab treatment of multiple sclerosis and related disorders: An observational study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104246"}}